Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 1
1982 3
1983 2
1984 2
1985 2
1986 6
1987 1
1988 3
1989 5
1990 6
1991 4
1992 8
1993 11
1994 21
1995 5
1996 21
1997 13
1998 22
1999 23
2000 17
2001 18
2002 15
2003 17
2004 35
2005 29
2006 31
2007 31
2008 49
2009 57
2010 58
2011 88
2012 103
2013 86
2014 113
2015 95
2016 131
2017 162
2018 161
2019 173
2020 195
2021 202
2022 212
2023 180
2024 192
2025 93

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,393 results

Results by year

Filters applied: . Clear all
Page 1
[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Singh S, et al. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851203 Clinical Trial.
BACKGROUND: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [(177)Lu]L …
BACKGROUND: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, …
Gastroenteropancreatic Neuroendocrine Tumors.
Cives M, Strosberg JR. Cives M, et al. CA Cancer J Clin. 2018 Nov;68(6):471-487. doi: 10.3322/caac.21493. Epub 2018 Oct 8. CA Cancer J Clin. 2018. PMID: 30295930 Free article. Review.
Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in …
Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They freque …
Gastroenteropancreatic Neuroendocrine Tumors.
Fernandes CJ, Leung G, Eads JR, Katona BW. Fernandes CJ, et al. Gastroenterol Clin North Am. 2022 Sep;51(3):625-647. doi: 10.1016/j.gtc.2022.06.002. Epub 2022 Aug 30. Gastroenterol Clin North Am. 2022. PMID: 36153114 Review.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common type of neuroendocrine tumors and are being increasingly identified in clinical practice. The diagnosis, staging, management, and surveillance of GEP-NETs rely heavily o …
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common type of neuroendocrine tumors …
Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T, Rottenburger C, Nicolas G, Wild D. Baumann T, et al. Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):45-57. doi: 10.1016/j.beem.2016.01.003. Epub 2016 Jan 20. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 26971843 Review.
Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). ...
Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainl …
Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review.
Cockburn KC, Toumi Z, Mackie A, Julyan P. Cockburn KC, et al. J Gastrointest Surg. 2021 Dec;25(12):3244-3257. doi: 10.1007/s11605-021-05115-w. Epub 2021 Sep 10. J Gastrointest Surg. 2021. PMID: 34506015 Free PMC article. Review.
BACKGROUND: Radioguided surgery (RGS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has been suggested as a way to improve intraoperative lesion detection. ...
BACKGROUND: Radioguided surgery (RGS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has been suggested a …
The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A. Granata V, et al. Radiol Oncol. 2019 Oct 25;53(4):373-387. doi: 10.2478/raon-2019-0040. Radiol Oncol. 2019. PMID: 31652122 Free PMC article. Review.
Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are a heterogeneous group of tumours. ...Conclusions The most appropriate imaging technique depends on the type of neuroendocrine tumour and the availability of specialized imaging tec …
Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are a heterogeneous group of tumours. ...Conclusion …
Gastroenteropancreatic neuroendocrine tumours: Clinicopathological evaluation at Shifa International Hospital, Islamabad.
Mamoon N, Naveed H, Abid M, Nasir H, Ahmad IN, Hameed Z, Khan AH. Mamoon N, et al. J Pak Med Assoc. 2021 Feb;71(2(A)):492-496. doi: 10.47391/JPMA.835. J Pak Med Assoc. 2021. PMID: 33819235
OBJECTIVE: Clinicopathological features of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have rarely been studied in Pakistani population. ...The most common histologic type was well differentiated neuroendocrine tumour (WDNET) in 96(81.4%) …
OBJECTIVE: Clinicopathological features of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have rarely been st …
Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.
Ritter AS, Poppinga J, Steinkraus KC, Hackert T, Nießen A. Ritter AS, et al. Curr Oncol Rep. 2025 Feb;27(2):157-167. doi: 10.1007/s11912-024-01632-4. Epub 2025 Jan 25. Curr Oncol Rep. 2025. PMID: 39862354 Free PMC article. Review.
PURPOSE OF REVIEW: Neuroendocrine tumours (NET) are rare entities arising from hormone producing cells in the gastroentero-pancreatic (GEP) tract. ...
PURPOSE OF REVIEW: Neuroendocrine tumours (NET) are rare entities arising from hormone producing cells in the gastroentero-pan …
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Chauhan A, et al. CA Cancer J Clin. 2024 Jul-Aug;74(4):359-367. doi: 10.3322/caac.21840. Epub 2024 Apr 29. CA Cancer J Clin. 2024. PMID: 38685134 Free article. Review.
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. ...Since publication …
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine …
2,393 results